Articles
-
5 days ago |
fiercebiotech.com | James Waldron
Kura Oncology and Kyowa Kirin have shared details of the phase 2 win for their oral leukemia treatment ziftomenib as the FDA mulls whether to greenlight the selective menin inhibitor. The trial of ziftomenib enrolled 92 heavily pretreated patients with relapsed or refractory (R/R) NPM1-mutant acute myeloid leukemia (AML).
-
5 days ago |
fiercebiotech.com | James Waldron
This time, Sanofi is making a $15 million upfront payment for the rights to NX-3911, a signal transducer and activator of transcription 6 (STAT6) degrader that could potentially treat inflammation in allergic conditions. Over time, Nurix could be eligible for up to $465 million in development, regulatory and commercial milestones as well as potential future royalties.
-
5 days ago |
fiercebiotech.com | James Waldron
Regeneron is paying Hansoh Pharma $80 million upfront for a phase 3-stage GLP-1/GIP receptor agonist the companies believe can hold its own against Eli Lilly’s Zepbound. As well as the upfront fee, Regeneron has agreed to pay up to $1.93 billion in development, regulatory and sales milestones to secure the ex-China rights to the asset, dubbed HS-20094.
-
5 days ago |
fiercebiotech.com | James Waldron
Actuate Therapeutics has set its sights on getting elraglusib approved for pancreatic cancer after the glycogen synthase kinase‐3 beta (GSK-3β) drug showed a three-month survival increase in a phase 2 study. The Texas- and Ireland-based biotech evaluated the therapy in a trial of 286 patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) who received either elraglusib and chemotherapy or chemotherapy alone.
-
5 days ago |
fiercebiotech.com | James Waldron
AstraZeneca has produced some fresh data to back up its blockbuster ambitions for camizestrant, tying the oral SERD to a 56% improvement in progression-free survival (PFS) in a phase 3 breast cancer study. The Serena-6 study had a novel design that reflected an unmet need in individuals with HR-positive, HER2-negative advanced breast cancer.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 2K
- Tweets
- 10K
- DMs Open
- No
Interesting to hear GSK CEO Emma Walmsley say that Big Pharma should "run towards" conversations about vaccine efficacy as the new U.S. admin approaches. My initial writeup of the #JPM2025 session is here... https://t.co/ir4daAfdFx
For this week's @FierceBiotech podcast, I caught up with @novonordisk's Marcus Schindler to talk about the future of GLP-1s and the lessons he's learned as Chief Scientific Officer https://t.co/82yunwgPuE
My dispatch from Day 1 of Jefferies 2024 - where everyone is now making the comparison with JPM (including the bad weather)
Jefferies London Healthcare Conference, which until last year had been a relatively cozy affair, has seemingly become a victim of its own success. Is the meeting the next JPM? https://t.co/Z1FVDYQX4e
